CPC A61K 38/465 (2013.01) [A61K 31/4985 (2013.01); A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C12N 9/16 (2013.01); C12Y 301/04035 (2013.01); A61K 2039/505 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] | 26 Claims |
1. A composition comprising an effector module, said effector module comprising a stimulus response element (SRE) and at least one payload which is operably linked to said SRE, wherein the SRE comprises a destabilizing domain (DD), wherein the DD comprises the catalytic domain of a human cGMP-specific 3′,5′-cyclic phosphodiesterase (hPDE5), wherein the DD comprises SEQ ID NO: 3, and wherein the DD further comprises a mutation in the amino acid at the position corresponding to amino acid 732 (R732) of SEQ ID NO: 1.
|